In this study, investigators are looking at the safety and efficacy of eyelash prostheses compared to 5.0% Lifitegrast BID Xiidra eye drops for dry eye disease. Participants will be split into the two groups and then be monitored and asked to report any adverse effects for 3-5 weeks.
40 patients will be randomly split into the two groups: one will receive 5.0% Lifitegrast BID eye drops and the other will be given eyelash prostheses. They will then be evaluated – 3 weeks after the eyelash prostheses and 5 weeks after the eye drops. The eye drops will be given immediately at the first visit after giving consent and the eyelash prostheses require the subjects to come in for a second study visit about 2 weeks later for the application.
- Self-reported dry eye symptoms
- Tear Break Up Time of less than 10 seconds as assessed by the Oculus Keratograph (see Appendix A).
- SPEED II Score greater than 25
- Men or Women, age between 50 and 90 inclusive
- Willingness to undergo both pre-treatment and post-treatment testing per the protocol
- Willingness to endure the 2-3 hour time required to place eyelash extensions, if randomized to this treatment arm
- Willingness to use eye drops for dry eyes and fill a prescription through insurance coverage, if randomized to this treatment arm
- Willingness to attend all study visits
- Willingness to sign informed consent and liability waiver
- Absence of eyelashes
- Eyelash disease such as clinically significant demodex, blepharitis, meibomitis
- Be unable or unwilling to give written informed consent and/or to comply with study procedures.
- Have any known hypersensitivity or contraindication to study treatments (including excipients), topical anesthetics or vital dyes.
- Be unable to demonstrate correct installation of over the counter (OTC) ocular lubricant during Visit 1.
- Have clinically significant ocular surface disease in either eye (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with study safety procedures, or assessments.
- Have clinically significant systemic disease (e.g., uncontrolled diabetes, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study at Visit 1 and 2.
- Current use of Restasis or Xiidra at the time of Visit 1
- Changes in the dose of, or the initiation of, any medications that are known to affect dry eyes within 90 days of Visit 1 or during the duration of the study.
- Any history of Herpes simplex of Herpes zoster affecting the eye or head.
Comprehensive Eye Care
Washington, Missouri, United States, 63039
Contact: Michael Korenfeld, MD 636-390-3999 email@example.com
Principal Investigator: Michael Korenfeld, MD
Sub-Investigator: Rita Hindmon
Clinical TrialsView All Clinical Trials
Study of Dark Adaptation in Age-Related Macular Degeneration
In this clinical trial, investigators are trying to see how effective dark adaptation protocol is in identifying…
OCT Biomarkers for Diabetic Retinopathy
In this study, investigators are seeing if standard optical coherence tomography (OCT) might be useful for…
Senofilcon A Lenses in Moderate to Severe Dry Eye Disease
In this clinical trial, investigators are studying how Senofilcon A daily contact lenses affect the treatment of…
Visual Function Tests in Age-Related Macular Degeneration
This study is looking to assess visual function tests in people with non-exudative age-related macular degeneration…
Trifocal Intraocular Lens Aberrometry Outcomes
Weill Medical College of Cornell University is holding a clinical trial on trifocal intraocular lens (IOL)…
Binocular Vision Anomalies After Cataract and Refractive Surgery
Salus University is holding a study on binocular vision disorders after cataract and corneal refractive surgery.…
Prophylactic Treatment: Lessdrops vs Standard Drops Regimen
Carolina Eyecare Physicians, LLC is holding a study on preventing inflammation and infection after cataract surgery…